Instruction for Authors  by unknown
1. Manuscript Submission
Manuscripts should be submitted by one of the below methods 
only.
1.1. Online Submission
Manuscripts (meaning all submission items, including all text, 
tables, artwork, cover letter, conflicts of interest disclosures, and 
any other required documents/material) may be submitted 
online to the JCMA through the Elsevier Editorial System 
(EES) at http://ees.elsevier.com/jcma. This site will guide 
authors stepwise through the submission process. If assistance is 
required, please refer to the tutorials for authors and/or cus-
tomer support that are available on the EES website; you may 
also contact the Editorial Office.
Editorial Office
Journal of the Chinese Medical Association
Chinese Medical Association
Taipei Veterans General Hospital
201, Section 2, Shih-Pai Road
Taipei 112, Taiwan, R.O.C.
Tel: (+886) (0)2 2871-2121 ext. 3043
Fax: (+886) (0)2 2877-1873
E-mail: jcma@vghtpe.gov.tw
1.2. Other Methods of Submission
If you are unable to submit your manuscript via the EES, you 
may submit your manuscript and related submission items as 
e-mail attachments to the JCMA Editorial Office.
Alternatively, you can submit your material on a CD-R and 
post it, together with 4 hard copies of your manuscript (that 
match the disk file exactly) and a copy of each of the required 
supporting documents, to the Editorial Office.
1.3. Important Information
l  Articles should be in Microsoft Word document format and 
prepared in the simplest form possible. We will add in the cor-
rect font, font size, margins and so on according to the 
Journal’s style.
l  You may use automatic page numbering, but do NOT use 
other kinds of automatic formatting such as footnotes, head-
ers and footers.
l  Put text, references, table headings and tables, and figure leg-
ends in one file.
l  Figures must be submitted as separate picture files, at the cor-
rect resolution and named according to the figure number 
and format, e.g., “Fig1.tif”, “Fig2.jpg”. Please see Section 
9.8. for more information.
1.4. Supporting Documents
The following documents must be included in your submission 
(refer also to the Checklist that follows these author instructions). 
Items (1), (2), (3), (4) and (5) are mandatory. Items (6), (7), 
(8) and (9) are required only if they are applicable to your 
manuscript.
(1)  Cover Letter. This must include the following information: 
•	 title of the manuscript
•	  names (spelled out in full) of all the authors*, and 
the institutions with which they are affiliated; indi-
cate all affiliations with a superscripted lowercase 
letter after the author’s name and in front of the 
matching affiliation (*the name of each author should 
be written with the family name last, e.g., Wan-Lin 
Chang)
•	  corresponding author details (name, e-mail, mailing 
address, telephone and fax numbers)
•	 e-mail address of the first author
•	  a statement that the material contained in the manu-
script has not been previously published and is not 
being concurrently submitted elsewhere
•	  persons who do not fulfill the requirements to be 
listed as authors but who nevertheless contributed 
to the manuscript (such as those who provided writ-
ing assistance, for example) should be disclosed
•	  list of manuscripts that have been published, sub-
mitted, or are in press that are similar to the submis-
sion to the JCMA (and include in your submission 
copies of those similar manuscripts so that JCMA 
Editors can be assured there is no overlap)
•	  your signature and those of ALL your coauthors
•	  Optional: if you have a list of reviewers who you 
wish to review or not to review your manuscript, 
you may include this list in the cover letter
(2)  Authorship Statement. Each author’s contribution to the 
manuscript should be listed. Please use the JCMA 
Authorship Statement form that follows these author 
instructions and that is also provided on the Journal’s 
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website at www.jcma-online.com. Your signature and those 
of ALL your coauthors must be included.
(3)  Conflicts of Interest Statement. Any and all potential and 
actual conflicts of interest should be listed. See Section 2 for 
more information. Please use the JCMA Conflicts of Interest 
Statement form that follows these author instructions and 
that is also provided on the Journal’s website at www.jcma-
online.com. Please ensure that the name of each author 
listed in your manuscript appears in either Section I or 
Section II of the form (an author’s name cannot appear in 
both Section I and Section II of the form). Your signature 
and those of ALL your coauthors must be included.
(4)  References Confirmation Statement. Authors are responsi-
ble for the accuracy and completeness of their references 
and for correct in-text citation. Please use the JCMA 
References Confirmation Statement form that follows these 
author instructions and that is also provided on the Journal’s 
website at www.jcma-online.com to certify that the refer-
ences in the submitted manuscript adhere to the format as 
detailed in Section 9.6. of these author instructions, and to 
confirm that you understand and agree that if massive cor-
rections to the references are found to be necessary in the 
event that your manuscript is accepted, JCMA Editors 
reserve the right to rescind the accept decision and reject 
the article.
(5)  Copyright Transfer Agreement. In the event that your 
manuscript is accepted for publication in the JCMA, you 
are required to transfer all copyright ownership in and relat-
ing to the work to the Chinese Medical Association and 
Elsevier. Please use the JCMA Copyright Transfer Agreement 
form that follows these author instructions and that is also 
provided on the Journal’s website at www.jcma-online.
com. Your signature and those of ALL your coauthors must 
be included.
(6)  Ethics Statement. Articles covering the use of human or 
animal samples in research, or human or animal experi-
ments must be accompanied by a letter of approval from the 
relevant review committee or authorities. See Section 3 for 
more information.
(7)  Consolidated Standards of Reporting Trials (CONSORT) 
flow chart for randomized controlled trials submitted for 
publication. See Section 4 for more information.
(8)  Signed Statement of Informed Consent. Articles where 
human subjects can be identified in descriptions, photo-
graphs or pedigrees must be accompanied by a signed 
statement of informed consent to publish (in print and 
online) the descriptions, photographs and pedigrees 
from each subject who can be identified. Please use the 
JCMA Consent Form for Publication of Photographs/
Information of Identifiable Patients that follows these 
author instructions and that is also provided on the 
Journal’s website at www.jcma-online.com. See Section 5 
for more information.
(9)  Copyright Permission. If you have reproduced or adapted 
material from other copyrighted sources, the letter(s) of 
permission from the copyright holder(s) to reproduce or 
adapt the copyrighted sources must be supplied. 
Otherwise, such material must be removed from your 
manuscript.
2. Disclosure of Conflicts of Interest
A conflict of interest occurs when an individual’s objectivity is 
potentially compromised by a desire for financial gain, promi-
nence, professional advancement or a successful outcome. 
JCMA Editors strive to ensure that what is published in the 
Journal is as balanced, objective and evidence-based as possible. 
Since it can be difficult to distinguish between an actual conflict 
of interest and a perceived conflict of interest, the Journal 
requires authors to disclose all and any potential conflicts of 
interest.
Conflicts of interest may be financial or non-financial. 
Financial conflicts include financial relationships such as 
honoraria; educational grants; participation in speakers’ 
bureaus; membership, employment, consultancies, stock 
ownership, or other equity interest; expert testimony or 
patent-licensing arrangements. Non-financial conflicts 
include personal or professional relationships, affiliations, 
academic competition, intellectual passion, knowledge or 
beliefs that might affect objectivity.
Please ensure that the name of each author listed in 
your manuscript appears in either Section I or Section II of 
the JCMA Conflicts of Interest Statement form (an author’s 
name cannot appear in both Section I and Section II of the 
form).
3. Ethical Approval of Studies and Informed Consent
For human or animal experimental investigations, appropriate 
institutional review board or ethics committee approval is 
required, and such approval should be stated in the methods 
section of the manuscript. For those investigators who do not 
have formal ethics review committees, the principles outlined in 
the Declaration of Helsinki should be followed (World Medical 
Association. Declaration of Helsinki: ethical principles for medical 
research involving human subjects. Available at: http://www.
wma.net/en/30publications/10policies/b3/17c.pdf).
For investigation of human subjects, state explicitly in the 
methods section of the manuscript that informed consent was 
obtained from all participating adult subjects and from parents 
or legal guardians for minors or incapacitated adults, together 
with the manner in which informed consent was obtained (e.g., 
oral or written).
For work involving animals, the guidelines for their care 
and use that were followed should be stated in the methods 
section of the manuscript. For those investigators who do 
not have formal institutional guidelines relating to animal 
experiments, the European Commission Directive 86/609/
EEC for animal experiments (available at http://ec.europa.
eu/environment/chemicals/lab_animals/legislation_en.
htm) should be followed and the same should be stated in 
the methods section of the manuscript.
4. Reporting Clinical Trials
All randomized controlled trials submitted for publication 
should include a completed Consolidated Standards of 
Reporting Trials (CONSORT) flow chart (please go to http://
www.consort-statement.org for more information). The JCMA 
has adopted the ICMJE proposal that requires, as a condition of 
consideration for publication of clinical trials, registration in a 
public trials registry. Purely observational studies (those in which 
the assignment of the medical intervention is not at the discre-
tion of the investigator) will not require registration. Further 
information can be found at http://www.icmje.org.
5. Identification of Patients in Descriptions, 
Photographs and Pedigrees
A signed statement of informed consent to publish (in print and 
online) patient descriptions, photographs and pedigrees should 
be obtained from all persons (parents or legal guardians for 
minors) who can be identified (including by the patients them-
selves) in such written descriptions, photographs or pedigrees. 
Please use the JCMA Consent Form for Publication of 
Photographs/Information of Identifiable Patients. Such persons 
should be shown the manuscript before its submission. 
Omitting data or making data less specific to de-identify patients 
is acceptable, but changing any such data is not acceptable. State 
explicitly in the methods section of the manuscript that informed 
consent was obtained from all participating adult subjects or 
from parents or legal guardians for minors or incapacitated 
adults, together with the manner in which informed consent 
was obtained (i.e., oral or written).
6. Previous Publication or Duplicate Submission
Submitted manuscripts are considered with the understanding 
that they have not been published previously in print or elec-
tronic format (except in abstract or poster form) and are not 
under consideration in totality or in part by another publication 
or electronic medium.
7. Basic Criteria
Articles should be written in English, using American English 
spelling, and meet the following basic criteria: the material is 
original, the information is important, the writing is clear and 
concise, the study methods are appropriate, the data are valid, 
and the conclusions are reasonable and supported by the data.
8. Article Categories
The categories of articles that are published in the Journal are 
listed and described below. Please select the category that best 
describes your paper. If your paper does not fall into any of these 
categories, please contact the Editorial Office.
8.1. Editorials
These are usually written by invited authors or editorial board 
members and are comments on recent news or articles pub-
lished in the Journal. Typical length: no more than 1200 words 
and not more than 15 references.
8.2. Review Articles
These should aim to provide the reader with a balanced over-
view of an important and topical issue in research or clinical 
practice. They should cover aspects of a topic in which scientific 
consensus exists as well as aspects that remain controversial and 
are the subject of ongoing scientific research. All articles and 
data sources reviewed should include information about the 
specific type of study or analysis, population, intervention, expo-
sure, and tests or outcomes. All articles or data sources should 
be selected systematically for inclusion in the review and criti-
cally evaluated. Figures, tables, algorithms and other forms of 
illustration should be included as appropriate.
Although many of the Review Articles published in the 
Journal are usually written by invited authors who are rec-
ognized experts on that particular topic, unsolicited 
Reviews are welcome and will be given due consideration.
Typical length: abstract, no more than 300 words; main 
text, no more than 3500 words and not more than 100 ref-
erences.
8.3. Original Articles
These articles typically include randomized trials, intervention 
studies, studies of screening and diagnostic tests, laboratory and 
animal studies, cohort studies, cost-effectiveness analyses, case-
control studies, and surveys with high response rates, which rep-
resent new and significant contributions to the field.
Section headings should be: Abstract, Introduction, 
Methods, Results, Discussion, Conflicts of Interest 
Statement (if any), Acknowledgments (if any), and 
References.
The Introduction should provide a brief background to 
the subject of the paper, explain the importance of the 
study, and state a precise study question or purpose.
The Methods section should describe the study design 
and methods (including the study setting and dates, 
patients/participants with inclusion and exclusion criteria, 
patient samples or animal specimens used, the essential fea-
tures of any interventions, the main outcome measures, the 
laboratory methods followed, or data sources and how 
these were selected for the study), and state the statistical 
procedures employed in the research.
The Results section should comprise the study results 
presented in a logical sequence, supplemented by tables 
and/or figures. Take care that the text does not repeat data 
that are presented in tables and/or figures. Only emphasize 
and summarize the essential features of the main results.
The Discussion section should be used to emphasize the 
new and important aspects of the study, placing the results 
in context with published literature, the implications of the 
findings, and the conclusions that follow from the study 
results.
Typical length: structured abstract, no more than 300 
words; main text, no more than 3000 words and not more 
than 60 references.
8.4. Case Reports
These are short discussions of a case or case series with unique 
features not previously described that make an important teach-
ing point or scientific observation. They may describe novel 
techniques or use of equipment, or new information on diseases 
of importance. Section headings should be: Abstract, 
Introduction, Case Report, Discussion, Conflicts of Interest 
Statement (if any), Acknowledgments (if any), and References.
The Introduction should describe the purpose of the 
present report, the significance of the disease and its specificity, 
and briefly review the relevant literature.
The Case Report should include statements of the prob-
lem, patient history, diagnosis, treatment, outcome and any 
other information pertinent to the case(s).
The Discussion should compare, analyze and discuss the 
similarities and differences between the reported case and 
similar cases reported in other published articles. The impor-
tance or specificity of the case should be restated when dis-
cussing the differential diagnoses. Suggest the prognosis of 
the disease and possibility of prevention.
Case reports should have no more than 6 authors. Typical 
length: abstract, no more than 200 words; main text, no 
more than 1200 words and not more than 20 references.
Authors should note that case reports are subject to the 
payment of peer-review fees and publication charges; please 
see Section 12 for more information.
8.5. Brief Communications
These may be prepared according to the format of Original 
Articles, but are expected to be concise presentations of prelimi-
nary experimental results, instrumentation and analytical tech-
niques, or aspects of clinical or experimental practice that are not 
fully investigated, verified or perfected but which may be of 
widespread interest or application. The Editors reserve the right 
to decide what constitutes a Brief Communication.
Brief communications should have no more than 6 
authors. Typical length: abstract, no more than 200 words; 
main text, no more than 1200 words and not more than 40 
references.
8.6. Letters to the Editor
Brief letters of constructive comments in response to previ-
ously published JCMA articles are welcome. Letters should 
have a title, no more than 4 authors, be no longer than 500 
words, and may include up to 10 references. Ensure that 
the corresponding author’s mailing and e-mail addresses are 
included. Letters are edited, sometimes extensively, to 
sharpen their focus. They may be sent for peer review at the 
discretion of JCMA Editors. Letters are selected based on 
clarity, significance, and space.
9. Manuscript Preparation
Text should be typed double-spaced on white A4 (297  210 
mm) paper, with outer margins of 2.5 cm. The manuscript 
should include a title page, abstract, keywords, text, conflicts of 
interest statement (if any), acknowledgments (if any), refer-
ences, and figures and tables as appropriate. Each section of the 
manuscript should begin on a new page. Pages should be num-
bered consecutively, beginning with the title page.
9.1. Title Page
The title page should contain the following information (in 
order, from the top to bottom of the page):
l article category
l article title
l  IMPORTANT: please do NOT include any author names 
and affiliations or corresponding author information on the 
title page (this information should be listed in your cover 
letter instead) because the JCMA follows a double-blind peer 
review process
9.2. Abstract and Keywords
An abstract and 3–5 relevant keywords (in alphabetical order) 
are required for the following article categories: Review Articles, 
Original Articles, Case Reports and Brief Communications.
Abstracts for Original Articles should be structured into 
the sections listed below and be no more than 300 words long.
Background: briefly explain the importance of the study 
topic and state a precise study question or purpose.
Methods: briefly introduce the methods used to perform 
the study; include information on the study design, setting, 
subjects, interventions, outcome measures and analyses as 
appropriate.
Results: briefly present the significant results, with data and 
statistical details such as p values where appropriate; be sure 
that information in the abstract matches that in the main text.
Conclusion: state the meaning of your findings, being 
careful to address the study question directly and to confine 
your conclusions to aspects covered in the abstract; give 
equal emphasis to positive and negative findings.
Abstracts for Case Reports should be unstructured (in 
one single paragraph with no section headings), no more 
than 200 words long, and include the significance and pur-
pose of the case presentation, the diagnostic methods of the 
case, the key data, and brief comments and suggestions 
with regard to the case.
Abstracts for Review Articles (not more than 300 
words) and Brief Communications (not more than 200 
words) should also be unstructured (in one single para-
graph with no section headings).
Keywords should be taken from the Medical Subject 
Headings (MeSH) list of Index Medicus (http://www.
nlm.nih.gov/mesh/meshhome.html).
No abstract or keywords are required for Editorials and 
Letters to the Editor.
9.3. Main Text
No author information such as names, affiliations and contact 
information should appear in the main text. The text for 
Original Articles and Brief Communications should be organ-
ized into the following sections: Introduction, Methods, 
Results, Discussion, Conflicts of Interest Statement (if any), 
Acknowledgments (if any), and References. Subheadings in 
long papers are acceptable if needed for clarification and ease of 
reading. Sections for Case Reports are: Introduction, Case 
Report, Discussion, Conflicts of Interest Statement (if any), 
Acknowledgments (if any), and References. Each section should 
begin on a new page.
9.3.1. Abbreviations
Where a term/definition will be continually referred to, it must 
be written in full when it first appears in the text, followed by the 
subsequent abbreviation in parentheses. Thereafter, the abbre-
viation may be used. An abbreviation should not be first defined 
in any section heading; if an abbreviation has previously been 
defined in the text, then the abbreviation may be used in a sub-
sequent section heading. Restrict the number of abbreviations 
to those that are absolutely necessary.
9.3.2. Numbers
Numbers that begin a sentence or those that are less than 10 
should be spelled out using letters. Centuries and decades 
should be spelled out, e.g., the Eighties or nineteenth century. 
Laboratory parameters, time, temperature, length, area, mass, 
and volume should be expressed using digits.
9.3.3. Units
Système International (SI) units must be used, with the excep-
tion of blood pressure values which are to be reported in 
mmHg. Use the metric system for the expression of length, 
area, mass, and volume. Temperatures are to be given in degrees 
Celsius.
9.3.4. Names of drugs, devices and other products
Use the Recommended International Non-proprietary Name 
(rINN) for medicinal substances, unless the specific trade name 
of a drug is directly relevant to the discussion. Generic drug 
names should appear in lowercase letters in the text. If a specific 
proprietary drug needs to be identified, the brand name may 
appear only once in the manuscript in parentheses following the 
generic name the first time the drug is mentioned in the text.
For devices and other products, the specific brand or trade 
name, the manufacturer and their location (city, state, country) 
should be provided the first time the device or product is men-
tioned in the text, for example, “…SPSS version 11 was used 
(SPSS Inc., Chicago, IL, USA)”. Thereafter, the generic term (if 
appropriate) should be used.
9.3.5. Gene nomenclature
Current standard international nomenclature for genes should 
be adhered to. For human genes, use genetic notation and sym-
bols approved by the HUGO Gene Nomenclature Committee 
(http://www.genenames.org). You may also refer to the 
resources available on PubMed at http://www.ncbi.nlm.nih.
gov/guide/genes-expression. The Human Genome Variation 
Society has a useful site that provides guidance in naming muta-
tions at http://www.hgvs.org/mutnomen/index.html. In 
your manuscript, genes should be typed in italic font and include 
the accession number.
9.3.6. Statistical requirements
Statistical analysis is essential for all research papers except Case 
Reports. Use correct nomenclature for statistical methods (e.g., 
two sample t test, not unpaired t test). Descriptive statistics 
should follow the scales used in data description. Inferential sta-
tistics are important for interpreting results and should be 
described in detail.
All p values should be presented to the third decimal 
place for accuracy. The smallest p value that should be 
expressed is p < 0.001 since additional zeros do not convey 
useful information; the largest p value that should be 
expressed is p > 0.99.
9.3.7. Personal communications and unpublished data
These sources cannot be included in the references list but 
may be described in the text. The author(s) must give the 
full name and highest academic degree of the person, the 
date of the communication, and indicate whether it was in 
oral or written (letter, fax, e-mail) form. A signed statement 
of permission should be included from each person identi-
fied as a source of information in a personal communication 
or as a source for unpublished data.
9.4. Conflicts of Interest Statement and/or Funding/
Support Statement
Since it is difficult to distinguish between an actual conflict 
of interest and a perceived conflict of interest, the JCMA 
requires authors to disclose all and any potential conflicts of 
interest and let readers judge for themselves. Therefore, 
please ensure that you provide information about any 
potential financial and non-financial conflicts of interest 
(see Section 2 for more information) in a concise paragraph 
after the main text.
All financial and material support for the research, work, 
writing and editorial assistance from internal or external 
agencies, including commercial companies, should be clearly 
and completely identified in a Funding/Support Statement.
9.5. Acknowledgments
After the Conflicts of Interest Statement and/or Funding/
Support Statement, general acknowledgments for consulta-
tions and statistical analyses should be listed concisely, 
including the names of the individuals who were directly 
involved. Consent should be obtained from those individu-
als before their names are listed in this section. Those 
acknowledged should not include secretarial, clerical or 
technical staff whose participation was limited to the per-
formance of their normal duties.
9.6. References
Authors are responsible for the accuracy and completeness of 
their references and for correct in-text citation.
9.6.1. In the main text, tables and figure legends
l  References should be indicated by superscripted numbers 
according to order of appearance in the text, and placed after 
punctuation. [The actual authors can be referred to, but the 
reference number(s) must always be given.]
l  References cited in tables or figure legends should be 
included in sequence at the point where the table or fig-
ure is first mentioned in the main text.
l  Do not cite abstracts unless they are the only available 
reference to an important concept.
l  Do not cite uncompleted work or work that has not yet 
been accepted for publication (i.e., “unpublished obser-
vation”, “personal communication”) as references. Also 
see Section 9.3.7.
9.6.2. In the references list
l  References should be compiled at the end of the manuscript 
according to the order of citation in the text.
l  References should be limited to those cited in the text only.
l  Journal references should include, in order, authors’ sur-
names and initials, article title, abbreviated journal name, year, 
volume and inclusive page numbers.
l  The surnames and initials of all the authors up to 6 should be 
included, but when authors number 7 or more, list the first 6 
authors only followed by “et al”.
l  Abbreviations for journal names should conform to those 
used in MEDLINE.
l  If citing a website, provide the author information, article title, 
website address and the date you accessed the information.
l  Reference to an article that is in press must state the journal 
name and, if possible, the year and volume.
Examples of the most common reference types are provided 
below. (Please pay particular attention to the formatting, word 
capitalization, spacing and style.)
Standard journal articles
Luo CB, Teng MM, Chang FC, Lin CJ, Guo WY, Chang CY. 
Stent-assisted coil embolization of intracranial aneurysms: a sin-
gle center experience. J Chin Med Assoc 2012;75:322–8.
Huang HK, Chiang CC, Hung SH, Su YP, Chiu FY, Liu CL, et 
al. The role of autologous bone graft in surgical treatment of 
hypertrophic nonunion of midshaft clavicle fractures. J Chin 
Med Assoc 2012;75:216–20.
Journal supplement
Kaplan NM. The endothelium as prognostic factor and thera-
peutic target: what criteria should we apply? J Cardiovasc 
Pharmacol 1998;32(Suppl 3):S78–80.
Journal article not in English but with English abstract
Hofele C, Schwager-Schmitt M, Volkmann M. Prognostic value 
of antibodies against p53 in patients with oral squamous cell 
carcinoma—five years survival rate. Laryngorhinootologie 
2002;81:342–5. [In German, English abstract]
Book with edition
Bradley EL. Medical and surgical management. 2nd ed. 
Philadelphia: Saunders; 1982.
Book with editors
Letheridge S, Cannon CR, editors. Bilingual education: teach-
ing English as a second language. New York: Praeger; 1980.
Book chapter in book with editor and edition
Greaves M, Culligan DJ. Blood and bone marrow. In: 
Underwood JCE, editor. General and systematic pathology. 4th 
ed. London: Churchill Livingstone; 2004, p. 615–72.
Book series with editors
Wilson JG, Fraser FC, editors. Handbook of teratology, vols. 1–4. 
New York: Plenum Press; 1977–1978.
Bulletin
World Health Organization. World health report 2002: reducing 
risk, promoting healthy life. Geneva, Switzerland: World Health 
Organization; 2002.
Electronic publications
Duchin JS. Can preparedness for biological terrorism save us 
from pertussis? Arch Pediatr Adolesc Med 2004;158(2). 
Available at http://archpedi.ama-assn.org/cgi/content/
full/158/2/106. Accessed June 12, 2004.
Smeeth L, Iliffe S. Community screening for visual impairment 
in the elderly. Cochrane Database Syst Rev 2002(2):CD001054. 
Doi:10.1002/14651858.CD1001054.
Item presented at a meeting but not yet published
Khuri FR, Lee JJ, Lippman SM. Isotretinoin effects on head 
and neck cancer recurrence and second primary tumors. In: 
Proceedings from the American Society of Clinical Oncology, 
May 31–June 3, 2003; Chicago, IL, abstract 359.
Item presented at a meeting and published
Cionni RJ. Color perception in patients with UV- or bluelight-
filtering IOLs. In: Symposium on cataract, IOL, and refractive 
surgery. San Diego, CA: American Society of Cataract and 
Refractive Surgery; 2004, abstract 337.
Thesis
Ayers AJ. Retention of resin restorations by means of enamel etch-
ing and by pins. MSD thesis, Indiana University School of 
Dentistry, Indianapolis, 1971.
Website
Glueckauf RL, Whitton J, Baxter J. Videocounseling for families 
of rural teens with epilepsy—project update. Telehealth News 
1998. Available at http://www.telehealth.net/subscribe/
newslettr_4a.html#1. Accessed November 15, 2008.
Company/manufacturer publications/pamphlets
Eastman Kodak Company, Eastman Organic Chemicals. 
Catalog no. 49. Rochester, NY: Eastman Kodak; 1977, p. 2–3.
ZstatFlu. Package insert. Oklahoma City, OK: ZymeTx Inc; 
2000.
9.7. Tables
Tables should supplement, not duplicate, the text. They 
should have a concise table heading, be self-explanatory, 
and numbered consecutively in the order of their citation in 
the text. Items requiring explanatory footnotes should be 
denoted using superscripted lowercase letters (a, b, c, etc.), 
with the footnotes arranged under the table in alphabetical 
order. Asterisks (*, **) are used only to indicate the proba-
bility level of tests of significance. Abbreviations used in the 
table must be defined and placed after the footnotes in 
alphabetical order. If you include a block of data or table 
from another source, whether published or unpublished, 
you must acknowledge the original source.
9.8. Figures
9.8.1. General guidelines
The number of figures should be restricted to the mini-
mum necessary to support the textual material. Figures 
should have an informative figure legend and be numbered 
in the order of their citation in the text. All symbols and 
abbreviations should be defined in the figure legend in 
alphabetical order. Items requiring explanatory footnotes 
should follow the same style as that for tables as described 
in Section 9.7.
Patient identification should be obscured. All lettering 
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A detailed guide on electronic artwork is available at http://
www.elsevier.com/artworkinstructions. Please note that the 
cost of color illustrations will be charged to the author (see 
Section 12 for more information).
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